Core Insights - Oruka Therapeutics successfully completed a go-public transaction, raising over $475 million, which provides a cash runway through multiple clinical inflection points [1][2] - The company is advancing its lead programs, ORKA-001 and ORKA-002, with accelerated clinical timelines [1][2] Corporate Updates - Oruka began trading on Nasdaq under the ticker ORKA after consummating its go-public transaction [2] - The company raised $275 million from a private placement and an additional $200 million from new and existing investors [2] Pipeline Developments - ORKA-001, a novel half-life extended IL-23p19 monoclonal antibody, is set to initiate a Phase 1 trial in Q1 2025, with interim data expected in H2 2025 [3] - ORKA-002, a novel half-life extended IL-17A/F monoclonal antibody, plans to start a Phase 1 trial in Q3 2025, with interim data anticipated in H1 2026 [4] Financial Performance - As of September 30, 2024, Oruka had cash and cash equivalents of $410.9 million, with a net cash usage of $27.8 million for Q3 2024 [5] - Research and Development (R&D) expenses for Q3 2024 totaled $25.7 million, including $7.8 million in non-cash stock-based compensation [6] - General and Administrative (G&A) expenses for Q3 2024 were $3.8 million, which included $2.4 million in personnel-related costs [7] - The net loss for Q3 2024 was $28.6 million, which included $9.0 million in non-cash stock-based compensation [8] Shares and Equity - Oruka has approximately 55.1 million shares of common stock and equivalents outstanding [9] - The company aims to provide patients with chronic skin diseases, such as plaque psoriasis, with high rates of complete disease clearance through infrequent dosing [10]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ACT OF 1934 For the transition period from ________ to ________ Commission file number: 000-22873 Oruka Therapeutics, Inc. (Exact name of registrant as specified in its charter) (650) 606-7910 (Registrant's ...

MENLO PARK, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced presentations at the following upcoming investor conferences: Stifel 2024 Healthcare ConferenceDate: Monday, November 18th, 2024Time: 2:25PM ET Jefferies London Healthcare ConferenceDate: Wednesday, November 20th, 2024Time: 2:00PM GMT A w ...